The authors concluded that Dacron or polytetrafluoroethylene grafts could be used for femoropopliteal bypass grafting with no significant differences in graft patency at five years when the autologous saphenous vein was unavailable. Acknowledged differences between trials plus lack of reporting of review methods, trial quality, and statistical comparison of patency rates make it difficult to assess reliability of the conclusion.
Sensitivity analysis was performed to examine the influence of individual trials.
The potential for publication bias was assessed using a funnel plot and Egger's test.
Results of the review
Seven RCTs were included (n=1,521 patients). Duration of follow-up ranged from two to ten years.
Pooled cumulative patency rates at five years were 49.2% (95% CI 45.6 to 52.7) for Dacron grafts and 38.4% (95% CI 32.2 to 44.6) for polytetrafluoroethylene grafts.
There was no statistically significant difference in the risk of graft occlusion between Dacron and polytetrafluoroethylene grafts (HR 0.87, 95% CI 0.67 to 1.12; random-effects model). Significant heterogeneity was found (p=0.03).
After excluding the trial that used fluoropolymer coated Dacron, Dacron grafts were associated with a significant reduction in the graft occlusion with no significant heterogeneity (HR 0.75, 95% CI 0.63 to 0.89; fixed-effect model).
For patients with above-knee femoropopliteal bypass grafts, Dacron grafts were associated with a significant reduction in graft occlusion compared with polytetrafluoroethylene grafts (HR 0.71, 95% CI 0.57 to 0.89; three trials; fixedeffect model).
There was no evidence of significant publication bias from Egger's test.
Authors' conclusions
Either Dacron or polytetrafluoroethylene grafts could be used for femoropopliteal bypass grafting with no significant differences in mid-term graft patency (49.2% versus 38.4% at five years) when the autologous saphenous vein was unavailable. Dacron grafts may be superior to polytetrafluoroethylene grafts for patency when they were not fluoropolymer-coated or when they were used in above-knee bypass grafting.
CRD commentary
The review question was clearly stated and inclusion criteria were appropriately defined. Several relevant sources were searched, but no attempts to minimise publication or language bias were reported. Methods used to select studies and extract data were not described, so it was not known whether efforts were made to reduce reviewer errors and bias.
Trial quality was not assessed, so results from these trials and any synthesis may not be reliable. Little information was provided about participants, which made it difficult to judge the general applicability of review findings. In addition, methods used to assess patency and definitions of patency and occlusion were not reported. Data were pooled using meta-analysis. Heterogeneity was assessed, and the trial responsible for heterogeneity was identified. The authors acknowledged the differences between trials for the type of Dacron graft and site of grafting.
The review statistically compared occlusion rates between graft types, but did not report any statistical comparison of patency rates, so it was not clear if results were comparable for patency. This, in addition to the lack of reporting of review methods and included trial quality, and lack of definitions and methods of determining occlusion and patency, makes it difficult to assess the reliability of the authors' conclusions.
